GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » CervoMed Inc (NAS:CRVO) » Definitions » Interest Coverage

CervoMed (CervoMed) Interest Coverage : No Debt (1) (As of Mar. 2024)


View and export this data going back to 1996. Start your Free Trial

What is CervoMed Interest Coverage?

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income by its Interest Expense. CervoMed's Operating Income for the three months ended in Mar. 2024 was $-2.60 Mil. CervoMed's Interest Expense for the three months ended in Mar. 2024 was $0.00 Mil. CervoMed has no debt. The higher the ratio, the stronger the company's financial strength is.

Good Sign:

CervoMed Inc has no debt.

(1) Note: For Interest Coverage, "No debt" indicates no long-term debt. An indication of "No Debt" does not necessarily mean that the company has no long-term debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

The historical rank and industry rank for CervoMed's Interest Coverage or its related term are showing as below:

CRVO' s Interest Coverage Range Over the Past 10 Years
Min: No Debt   Med: No Debt   Max: No Debt
Current: No Debt


CRVO's Interest Coverage is ranked better than
99.42% of 343 companies
in the Biotechnology industry
Industry Median: 148.11 vs CRVO: No Debt

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.


CervoMed Interest Coverage Historical Data

The historical data trend for CervoMed's Interest Coverage can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Note: For Interest Coverage, "No debt" indicates no long-term debt. An indication of "No Debt" does not necessarily mean that the company has no long-term debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

* Premium members only.

CervoMed Interest Coverage Chart

CervoMed Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Interest Coverage
Get a 7-Day Free Trial Premium Member Only Premium Member Only N/A N/A No Debt - No Debt

CervoMed Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Interest Coverage Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only No Debt No Debt No Debt No Debt No Debt

Competitive Comparison of CervoMed's Interest Coverage

For the Biotechnology subindustry, CervoMed's Interest Coverage, along with its competitors' market caps and Interest Coverage data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


CervoMed's Interest Coverage Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, CervoMed's Interest Coverage distribution charts can be found below:

* The bar in red indicates where CervoMed's Interest Coverage falls into.



CervoMed Interest Coverage Calculation

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense:

If Interest Expense is negative and Operating Income is positive, then

Interest Coverage=-1* Operating Income /Interest Expense

Else if Interest Expense is negative and Operating Income is negative, then

The company did not have earnings to cover the interest expense.

Else if Interest Expense is 0 and Long-Term Debt & Capital Lease Obligation is 0, then

The company had no debt (1).


Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

CervoMed's Interest Coverage for the fiscal year that ended in Dec. 2023 is calculated as

Here, for the fiscal year that ended in Dec. 2023, CervoMed's Interest Expense was $0.00 Mil. Its Operating Income was $-7.81 Mil. And its Long-Term Debt & Capital Lease Obligation was $0.00 Mil.

CervoMed had no debt (1).

CervoMed's Interest Coverage for the quarter that ended in Mar. 2024 is calculated as

Here, for the three months ended in Mar. 2024, CervoMed's Interest Expense was $0.00 Mil. Its Operating Income was $-2.60 Mil. And its Long-Term Debt & Capital Lease Obligation was $0.00 Mil.

CervoMed had no debt (1).

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

The higher the ratio, the stronger the company's Financial Strength is.


CervoMed  (NAS:CRVO) Interest Coverage Explanation

Ben Graham requires that a company has a minimum interest coverage of 5 with the companies he invested. If the interest coverage is less than 2, the company is burdened by debt. Any business slow or recession may drag the company into a situation where it cannot pay the interest on its debt.

Interest Coverage is an important factor when GuruFocus ranks a company's overage Financial Strength .


CervoMed Interest Coverage Related Terms

Thank you for viewing the detailed overview of CervoMed's Interest Coverage provided by GuruFocus.com. Please click on the following links to see related term pages.


CervoMed (CervoMed) Business Description

Traded in Other Exchanges
N/A
Address
20 Park Plaza, Suite 424, Boston, MA, USA, 02216
CervoMed Inc Formerly Diffusion Pharmaceuticals Inc is a clinical-stage biotechnology company. It is focused on extending the life expectancy of cancer patients by improving the effectiveness of current standard-of-care treatments, including radiation therapy and chemotherapy. The company's product candidate is trans sodium crocetinate (TSC), which is used for the treatment of glioblastoma multiforme (GBM) and metastatic brain cancer. Geographically business activity of the firm functions through the region of the United States.
Executives
Frank Zavrl director C/O PUMA BIOTECHNOLOGY INC., 10880 WILSHIRE BOULEVARD, SUITE 2150, LOS ANGELES CA 90024
Sylvie Gregoire director, 10 percent owner 940 WINTER STREET, C/O PERKINELMER, WALTHAM MA 02451
John William Tanner officer: Chief Financial Officer C/O EIP PHARMA, INC., 20 PARK PLAZA, SUITE 424, BOSTON MA 02116
Kelly Blackburn officer: VP, Clinical Development C/O ATYR PHARMA, INC., 3545 JOHN HOPKINS COURT, SUITE 250, SAN DIEGO CA 92121
Marwan Sabbagh director C/O CORTEXYME, INC., 269 EAST GRAND AVE., SOUTH SAN FRANCISCO CA 94080
John J Alam director, 10 percent owner, officer: CEO and President 130 WAVERLY STREET, CAMBRIDGE MA 02139
Jeffrey V. Poulton director 300 THIRD STREET, CAMBRIDGE MA 02142
Jill Davidson director 300 EAST MAIN STREET, SUITE 101, CHARLOTTESVILLE VA 22902
Raven Jaeger officer: Chief Regulatory Officer 300 EAST MAIN STREET, SUITE 201, CHARLOTTESVILLE VA 22902
Eric Francois director C/O SCYNEXIS, INC., 3501 C TRICENTER BOULEVARD, DURHAM NC 27713
Diana M Lanchoney director 1317 CARLTON AVE, SUITE 200, CHARLOTTESVILLE VA 22902
William Robert Elder officer: GC & Secretary 1317 CARLTON AVENUE, SUITE 200, CHARLOTTESVILLE VA 22902
Cobuzzi Robert Joseph Jr. director C/O DIFFUSION PHARMACEUTICALS INC., 1317 CARLTON AVENUE, SUITE 200, CHARLOTTESVILLE VA 22902
Christopher D Galloway officer: Chief Medical Officer 1317 CARLTON AVENUE, SUITE 200, CHARLOTTESVILLE VA 22902
Jane H Hollingsworth director DIFFUSION PHARMACEUTICALS INC., 1317 CARLTON AVENUE, SUITE 200, CHARLOTTESVILLE VA 22902

CervoMed (CervoMed) Headlines

From GuruFocus